Whilst we have seen the COVID pandemic wreak havoc on care pathways across the country, it has also spurred closer and more concentrated working relationships between all factions of healthcare, with the common goal of improving outcomes for patients. And so learnings from this year’s Patient Partnership Index (p20) should be more pertinent now than ever before, helping pharma to keep patients at the centre of all that it does amid these particularly challenging times. A huge congratulations to Gilead Sciences, Leo Pharma (UK) and Pfizer, which all achieved GOLD standard for their entries.
Also with patients firmly in mind, on page 17 John Pinching considers how a growing confidence in the life sciences industry and the currency of individual experience is giving patient centricity an injection of new life, while on page 24 Oli Hudson outlines six different ways the industry has partnered with the NHS, all mutually beneficial while ultimately improving services for patients.
Elsewhere, David Sant provides fascinating insight into the debate over patent waivers for COVID vaccines and technology (p34), while Chris Smith, Robin Ellis and Pete Sadler urge pharma companies to be prepared for standard-essential patents, which are coming to the industry in one way or another (p32).
Finally, another reminder that the 2021 PharmaTimes Marketer of the Year, Communications Awards and Sales Awards are open for entry, while tickets are still on sale for the International Clinical Researcher of the Year gala dinner. For more information visit www.pharmatimes.com/competitions
Growing confidence in the life sciences industry and the currency of individual experience has given patient centricity an injection of new life. It has also been essential in suppressing the coronavirus and establishing humanity’s position in the race against time
Jenny Ousbey outlines what we’ve learnt from the Patient Partnership Index 2021
Five ways the pandemic is going to revolutionise our industry
Collaborative working is a cornerstone of the government’s White Paper for the NHS, but how can pharmaceutical companies best get in on the act? Wilmington Healthcare’s Oli Hudson looks at six distinct ways in which industry can partner with NHS organisations to mutual advantage
How the healthcare sector can learn from the ad industry to better engage target audiences and improve education
Pharma R&D activity surges even without COVID-19
Standard-essential patents are coming to the pharmaceutical industry
In recent months an intense debate has arisen about a potential waiving of patent rights on COVID vaccines. This article looks at the background to this debate, the relevance of patent rights to the COVID vaccines and the various issues raised by the different protagonists.
PharmaTimes talks to Juliet Bauer about her role as MD of Livi UK and the digital healthcare landscape
Medical congresses can learn important lessons from how consumer brands have adapted to a COVID world
Sustainability commitments alone won’t stop the climate crisis
The healthcare industry has successfully brought effective vaccines to market despite massive disruption from COVID-19. But with global supply chains still stretched, what are the priorities for supply chain players as we move towards a ‘new normal’?
MAGAZINE EXCLUSIVE
How tech is enabling a more representative future for pharma
MAGAZINE EXCLUSIVE
